2022 World Conference on Lung Cancer (ePosters)-EP08.02-046. Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)

EP08.02-046. Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)

Back to course

Pdf Summary

A retrospective observational multicenter study called ARTICUNO investigated the activity of the drug Osimertinib in patients with advanced non-small cell lung cancer (NSCLC) with uncommon mutations in the EGFR gene. Osimertinib is a targeted therapy drug typically used to treat NSCLC with classical EGFR mutations. However, the effectiveness of Osimertinib in NSCLC with uncommon EGFR mutations is not well understood.<br /><br />The study included 50 patients from 13 institutions in Italy who were treated with Osimertinib since August 2017. The researchers collected data on response rates, progression-free survival, duration of response, and overall survival. The main clinical and biological characteristics of the study population were recorded.<br /><br />The results showed that Osimertinib had a response rate of 49% and a disease control rate of 85% in the overall evaluable population. These rates were slightly higher in the TKI-naïve (treatment-naïve) group, with a response rate of 53% and a disease control rate of 84%. The median progression-free survival in the TKI-naïve group was 11 months, and the median duration of response was 14 months.<br /><br />The study concluded that Osimertinib demonstrated activity in about half of the patients with NSCLC and uncommon EGFR mutations. The results of the study are consistent with those reported in a previous trial conducted in Korea with Osimertinib and with another drug called Afatinib. The ARTICUNO study is still ongoing, and more data will be presented in the future.<br /><br />Overall, this study provides valuable insights into the use of Osimertinib in NSCLC patients with uncommon EGFR mutations and highlights the need for further research in this area.

Asset Subtitle

Elio Gregory Pizzutilo

Meta Tag

Speaker Elio Gregory Pizzutilo

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

retrospective

observational

ARTICUNO

Osimertinib

NSCLC

uncommon mutations

response rates

progression-free survival

TKI-naïve group

further research